SWINBURNE UNIVERSITY OF TECHNOLOGY

Swinburne University and Tryptamine Therapeutics Launch World-First Intravenous Psilocin Trial for Binge Eating Disorder

a month ago

• Tryptamine Therapeutics and Swinburne University have signed an agreement to conduct the world's first clinical trial using intravenous psilocin (TRP-8803) to treat Binge Eating Disorder, with recruitment beginning this quarter. • The open-label trial will enroll 12 participants across two dosage cohorts, building on promising Phase 2a results that showed an earlier oral formulation reduced binge eating episodes by more than 80%. • Binge Eating Disorder, the most common eating disorder in the United States, currently has no specifically approved therapies, highlighting the significant unmet medical need this novel psychedelic-assisted treatment aims to address.

Pila Pharma's XEN-D0501 Shows Promise in Preclinical Abdominal Aortic Aneurysm Study

4 months ago

• Pila Pharma's XEN-D0501, a TRPV1 antagonist, significantly reduced abdominal aorta aneurysm growth in mice by over 50% compared to placebo, demonstrating preclinical proof-of-concept. • XEN-D0501 has shown good tolerability in Phase 2a trials involving individuals with obesity and type 2 diabetes, enhancing insulin response and reducing cardiovascular biomarkers. • A Phase 2a trial (PP-CT03) is planned to identify the maximum tolerable dose of XEN-D0501 in obese and type 2 diabetic patients, evaluating its safety profile over a 3-month treatment period. • While early data are promising, researchers urge caution, emphasizing the need for more quality human data to fully understand XEN-D0501's potential in treating metabolic and cardiovascular diseases.